Glenmark's Glenn Saldanha takes over as president of pharma lobby group IPA

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol News
Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals has taken over as the President of domestic pharmaceutical lobby group Indian Pharmaceutical Alliance (IPA).

Saldanha who replaces Nilesh Gupta, the Managing Director of Lupin will be in office for next two years.

Rajesh Jain, Joint Managing Director of Panacea Biotec was named as the new Vice President of IPA.

The IPA, initially formed by eight large Indian drug makers in November 1999 has now 20 pharmaceutical companies in its fold.

Collectively, the IPA members account for almost 85 per cent of the private sector investment in pharmaceutical research and development, contribute 80 per cent of the country’s exports of drugs and pharmaceuticals, service over 46 per cent of the domestic market, and account for 46 percent of total sales of essential medicines.

“The IPA in a short span of 17 years has emerged as a credible alternative capable of caring for all stakeholders in the pharmaceutical industry,” DG Shah, Secretary General of IPA said in a statement.

“It has grasped the emerging scenario and has worked with the Government to steer the local industry to new heights and be counted in the world,” Shah said.

IPA in 2000 has launched a campaign against spurious drugs that involved identifying and prosecuting manufacturers and distributors of spurious drugs. The lobby group also constituted an Intellectual Property Cell in 2009 to pro-actively challenge secondary patents at the pre-grant stage.

In recent times – the industry body constituted a Quality Forum (QF) focused on attaining quality excellence, and address various regulatory issues faced by the Indian pharmaceutical industry.